Results 51 to 60 of about 222 (118)

Clinical Application of Peripheral Blood Biomarkers for Solid Tumors

MedComm, Volume 7, Issue 3, March 2026.
Peripheral blood biomarkers provide a minimally invasive, dynamic, and potentially more accurate means to obtain a comprehensive tumor profile. Technologies for detecting them are advancing, and with the help of artificial intelligence, they are being used more and more often for cancer diagnosis, prognostic assessment, and therapeutic monitoring ...
Xinru Tu, Mengyan Tu, Junfen Xu
wiley   +1 more source

Abstract Book for the 27th Congress of the European Hematology Association

, 2022
HemaSphere, Volume 6, Issue S3, Page 1-4130, June 2022.
wiley   +1 more source

Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study

Cancer Science, Volume 116, Issue 1, Page 248-256, January 2025.
We constructed a lung cancer detection model using four circulating free DNA (cfDNA) fragmentation features, and this model exhibits strong screening capabilities. It is not only effective for early cancer screening in asymptomatic individuals but also demonstrates robust detection capabilities in early cancer diagnosis.
Fudong Xu, Chong Wang, Hongxia Li, Bo Yu, Luyuan Chang, Feng Wang, Chaolian Long, Ling Bai, Hanqing Zhao, Nanying Che   +9 more
wiley   +1 more source

EHA2021 Virtual Congress Abstract Book

, 2021
HemaSphere, Volume 5, Issue S2, June 2021.
wiley   +1 more source

Transformer‐based representation learning and multiple‐instance learning for cancer diagnosis exclusively from raw sequencing fragments of bisulfite‐treated plasma cell‐free DNA

Molecular Oncology, Volume 18, Issue 11, Page 2755-2769, November 2024.
This study introduces DECIDIA, a deep‐learning approach for early cancer diagnosis using bisulfite‐treated cfDNA sequencing fragments. Utilizing transformer‐based representation learning and weakly supervised multiple‐instance learning, DECIDIA accurately detects cancer and predicts cancer types, significantly simplifying data analysis.
Jilei Liu, Hongru Shen, Yichen Yang, Meng Yang, Qiang Zhang, Kexin Chen, Xiangchun Li   +6 more
wiley   +1 more source

Circulating Cell-free DNA Fragmentomics Detection and Beyond

aging and disease
Circulating cell-free DNA (cfDNA) comprises DNA fragments released into bodily fluids via apoptosis, necrosis, or phagocytosis. cfDNA encapsulates both fragmentomics (structural) and non-fragmentomics (sequence/epigenetic) information from source cells, thereby representing a promising biomarker.
Tianliang, Liu, Zhicheng, Li, Shifu, Chen, Jiasheng, Zhong   +3 more
openaire   +2 more sources

Plasma Cell‐Free DNA Concentration and Fragmentomes Predict Neoadjuvant Chemotherapy Response in Cervical Cancer Patients

Advanced Science, Volume 11, Issue 43, November 20, 2024.
Cervical cancer patients with varying responses to neoadjuvant chemotherapy (NACT) exhibit unique patterns of variation in cell‐free DNA (cfDNA) levels and fragmentomic characteristics. The cfDNA emerges as a promising biomarker for predicting tumor response to NACT in cervical cancer, offering a novel approach for monitoring treatment response to ...
Ting Peng, Haiqiang Zhang, Lingguo Li, Canhui Cao, Miaochun Xu, Xiaojie Liu, Shitong Lin, Ping Wu, Tian Chu, Binghan Liu, Yashi Xu, Yan Zhang, Yeqin Wang, Jinjin Yu, Wencheng Ding, Xin Jin, Peng Wu   +16 more
wiley   +1 more source

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges

MedComm, Volume 5, Issue 11, November 2024.
The origin of ctDNA in the bloodstream is derived from CTC, exosomes secreted by tumor cells, apoptotic tumor cells and necrotic tumor cells (A). ctDNA methylation status plays an important role in the occurrence and development of cancer and is a biomarker for tumor liquid biopsy.
Lingyu Li, Yingli Sun
wiley   +1 more source

Advances in early detection of non‐small cell lung cancer: A comprehensive review

Cancer Medicine, Volume 13, Issue 18, September 2024.
Abstract Background Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and ...
Nour Kenaan, George Hanna, Moustafa Sardini, Mhd Omar Iyoun, Khedr Layka, Zein Alabdin Hannouneh, Zuheir Alshehabi   +6 more
wiley   +1 more source

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Nature Communications
Abstract Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling.
Kyle T. Helzer, Marina N. Sharifi, Jamie M. Sperger, Matthew R. Chrostek, Matthew L. Bootsma, Shannon R. Reese, Amy Taylor, Katie R. Kaufmann, Hannah Krause, Jennifer Schehr, Nan Sethakorn, David Kosoff, Christos E. Kyriakopoulos, Michael Bassetti, Grace Blitzer, John Floberg, Martin Sjöström, Andrew J. Armstrong, Himisha Beltran, Rana R. McKay, Felix Y. Feng, Ruth O’Regan, Kari B. Wisinski, Hamid Emamekhoo, Alex W. Wyatt, Joshua M. Lang, Shuang G. Zhao   +26 more
openaire   +3 more sources